Fig. 5

Characterization of HLA-A2, HLA-A11, HLA-24, and HLA-B44 restricted HPV18 E6-specific CD8 + T cell responses generated by therapeutic HPV vaccine in different human MHC class I transgenic mice. Female human MHC class I transgenic mice (5 per group) were vaccinated and cells were prepared as described in Fig. 4. For HLA-A2 mice (A, B), 12 days after the last vaccination in the HLA-A2 transgenic mice, the splenocytes from the mice were prepared and stimulated with C1R-AAD, C1R-D^b, or C1R-K^b cells pulsed with HPV18 E6 peptide in the presence of GolgiPlug overnight. The cells were then stained, and acquired as described prior. A. Flow cytometry analyses of HPV18 E6-specific CD8 + T cells generated by vaccinated HLA-A2 transgenic mice (left hand panel) or following pulsing with C1R-AAD, C1R-D^b, or C1R-K^b cells pulsed with HPV18 E6aa24-33 (right hand panel). B Flow cytometry analyses of HPV18 E6-specific CD8 + T cells generated by vaccinated HLA-A2 transgenic mice (left hand panel) or following pulsing with C1R-AAD, C1R-D^b, or C1R-K^b cells pulsed with HPV18 E6aa97-105 (right hand panel). Bar graph of flow cytometry analysis of HPV18 E6-specific CD8 + T cells generated by vaccinated (C) HLA-A11 (D) HLA-A24 or (E) HLA-B44 transgenic mice